Nature Communications (Sep 2022)
Neutralization of hepatitis B virus with vaccine-escape mutations by hepatitis B vaccine with large-HBs antigen
- Ayaka Washizaki,
- Asako Murayama,
- Megumi Murata,
- Tomoko Kiyohara,
- Keigo Yato,
- Norie Yamada,
- Hussein Hassan Aly,
- Tomohisa Tanaka,
- Kohji Moriishi,
- Hironori Nishitsuji,
- Kunitada Shimotohno,
- Yasumasa Goh,
- Ken J. Ishii,
- Hiroshi Yotsuyanagi,
- Masamichi Muramatsu,
- Koji Ishii,
- Yoshimasa Takahashi,
- Ryosuke Suzuki,
- Hirofumi Akari,
- Takanobu Kato
Affiliations
- Ayaka Washizaki
- Center for the Evolutionary Origins of Human Behavior, Kyoto University
- Asako Murayama
- Department of Virology II, National Institute of Infectious Diseases
- Megumi Murata
- Center for the Evolutionary Origins of Human Behavior, Kyoto University
- Tomoko Kiyohara
- Department of Virology II, National Institute of Infectious Diseases
- Keigo Yato
- Department of Virology II, National Institute of Infectious Diseases
- Norie Yamada
- Department of Virology II, National Institute of Infectious Diseases
- Hussein Hassan Aly
- Department of Virology II, National Institute of Infectious Diseases
- Tomohisa Tanaka
- Department of Microbiology, Graduate School of Medicine, University of Yamanashi
- Kohji Moriishi
- Department of Microbiology, Graduate School of Medicine, University of Yamanashi
- Hironori Nishitsuji
- Department of Virology and Parasitology, Fujita Health University School of Medicine
- Kunitada Shimotohno
- Genome Medical Sciences Project, National Center for Global Health and Medicine
- Yasumasa Goh
- Research Laboratory, Beacle, Inc.
- Ken J. Ishii
- Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo
- Hiroshi Yotsuyanagi
- Division of Infectious Diseases, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo
- Masamichi Muramatsu
- Department of Virology II, National Institute of Infectious Diseases
- Koji Ishii
- Department of Quality Assurance, Radiation Safety, and Information System, National Institute of Infectious Diseases
- Yoshimasa Takahashi
- Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases
- Ryosuke Suzuki
- Department of Virology II, National Institute of Infectious Diseases
- Hirofumi Akari
- Center for the Evolutionary Origins of Human Behavior, Kyoto University
- Takanobu Kato
- Department of Virology II, National Institute of Infectious Diseases
- DOI
- https://doi.org/10.1038/s41467-022-32910-z
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 12
Abstract
The hepatitis B vaccine is recognised as the most effective approach in reducing hepatitis-B-related morbidity; vaccine-escape mutations are however capable of infecting vaccinated individuals. In this work, authors aim to establish a hepatitis B vaccine candidate, which they assess in rhesus macaques in terms of efficacy and safety.
